Online inquiry

IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8631MR)

This product GTTS-WQ8631MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8631MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10610MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ12717MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ8060MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ6602MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ12267MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ13993MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ3088MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ8797MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW